Scientific breakthrough on objective diagnosis of PTSD
(Thomson Reuters ONE) -
* Scientific breakthrough for non-invasive, automatic, objective diagnosis of
PTSD leveraging autonomic biomarkers
* Accuracy of 80% (+/- 1%) for objectively diagnosing subjects with PTSD
* Medibio has exclusive worldwide rights to commercialise the technology
SYDNEY, Australia and MINNEAPOLIS, June 26, 2017 (GLOBE NEWSWIRE) -- Australian
Stock Exchange-listed medical technology company Medibio Limited (MEB or
the Company) announces a new research study, conducted at Emory University,
Atlanta GA and funded by Medibio, demonstrates that post-traumatic stress
disorder (PTSD) can be accurately diagnosed using a non-invasive protocol
involving heart rate data and machine learning algorithms. The research was
based on technology developed at Emory University and licensed by Medibio.
The research is described in a paper titled "Classification of post-traumatic
stress disorder from heart rate variability metrics with heart rate-based window
segmentation," published in the June issue of Physiological Measurement. Emory
researchers Gari Clifford, DPhil, MSc, MA, and Amit Shah, MD, MSCR, achieved an
accuracy of 80% (+/- 1%) for objectively diagnosing subjects with PTSD and
differentiating them from those without PTSD using 24-hour heart rate data and
machine learning algorithms.
The researchers noted that, "Our results suggest the potential for a non-
invasive tool to objectively track PTSD status."
Medibio's collaboration with Emory was announced in January 2017 and is aimed at
expanding the use of the technology beyond depression to classifying post-
traumatic stress disorder. Under a license agreement, Medibio has the exclusive
option and worldwide rights to commercialise new discoveries based on the PTSD
diagnostic and monitoring technology developed by Clifford and Shah. The license
agreement extends and further solidifies Medibio's intellectual property
position and enables the company to service the vast veterans affairs and
military clinical markets.
The research was conducted in collaboration with the Department of Veterans
Affairs, using its twins database. It is part of a broader ongoing initiative
between Emory University and Medibio. A full copy of the paper will be made
available on Medibio's website.
Emory's approach used features extracted from quiescent segments, or periods
with lowest heart rate (HR), rather than features calculated from the entire 24
hours of ECG heart rate data. The paper states that "Overall, these findings
underscore physiologic changes that occur with PTSD, particularly during periods
of relative HR quiescence."
The paper concludes that "Our approach of estimating PTSD status from Heart Rate
Variability features is non-invasive, automatic, objective, and potentially
useful for monitoring progression and/or improvement of a condition". It
suggests that "future studies could evaluate if this classifier reflects changes
with effective treatment and resolution of PTSD."
"We appreciate the research done by Emory University and our collaboration. The
findings from this research provide a significant step forward in assisting
veterans by identifying and diagnosing PTSD. This technology will also assist
in the direct benefit for screening, diagnosing and treating mental illness
among active military service personnel. We look forward to future research and
commercial activity in the critical areas of veterans mental health diagnosis
and management," said Jack Cosentino, Medibio CEO. "In the United States, over
22 veterans a day commit suicide due to PTSD and mental illness. This
technology will change the way care is delivered to millions of people around
the world."
About PTSD
PTSD is a chronic disabling psychiatric condition, with prevalence rates of
3.5% in the general US population(1) and 11-30% amongst returning US service
members(2). The disorder represents a significant and costly illness to
veterans, their families, and society. The US Congressional Budget Office has
reported that the annual cost of treating a veteran with PTSD is US$8,300. There
are 18.8 million veterans in the US including 2.3 million troops deployed in
Iraq and Afghanistan over the past 10 years.
Principal researchers
Dr. Gari Clifford, DPhil, MSc, MA, has an international reputation in mHealth
and critical care data analysis and the application of signal processing and
machine learning to medicine. He joined the faculty at Emory and Georgia Tech in
2014 as an associate professor in the departments of Biomedical Engineering and
Bioinformatics, where he is now the interim chair. Previously, as an Associate
Professor at the University of Oxford, Dr. Clifford helped found and led one of
the five themes at its Sleep & Circadian Neuroscience Institute, where he is now
an Honorary Professor. Prior to that, Dr. Clifford was a Principal Research
Scientist at MIT, where he managed the collection and dissemination for the
world's largest open access hospital database. His research interests focus on
machine learning and signal processing for data fusion, prediction and
developing confidence intervals and trust metrics. Application areas in health:
critical care, mHealth, sleep and circadian rhythms, and resource-constrained
environments.
Dr. Amit Shah, MD, MSCR, is an Assistant Professor of Epidemiology with an
adjunct appointment in Medicine (Cardiology) at Emory University, and a
practicing cardiologist. He is an expert in the study of autonomic function and
psychological risk factors for heart disease, and much of his research focuses
on understanding the cardiovascular pathophysiology of depression and
posttraumatic stress disorder. His training has largely been dedicated to
studying the psychophysiology of PTSD, including circadian abnormalities
associated with the condition. Recently, his work on PTSD and abnormal circadian
rhythm was presented at the American Psychosomatic Society conference.
Disclosure: As inventors and licensees, Drs. Clifford and Shah and Emory
University are eligible to benefit financially from this technology. This
relationship has been reviewed and is managed by Emory University through its
Conflict of Interest office.
About Medibio Limited
Medibio (ASX:MEB) (OTCQB:MDBIF), headquartered in Melbourne, Australia, with US
headquarters in Minneapolis, Minnesota, is an evidence-based medical technology
company that has developed an objective test to assist in the diagnosis and
management of depression, chronic stress and other mental health disorders.
Based on research conducted over 15 years at the University of Western
Australia, this test utilizes a panel of patented (and patent pending)
circadian, sleep and autonomic system biomarkers to objectively quantify and
characterize mental state. Medibio's depression diagnostic is being validated
in clinical studies undertaken by Johns Hopkins University School of Medicine
and The University of Ottawa, among others. The clinical trials will support
Medibio's application to become the first FDA approved, objective, and evidence
based approach to the diagnosis of mental health disorders. Medibio's technology
also provides an objective method for the assessment of stress and mental
wellbeing that can be translated to the workplace stress/wellbeing market,
wearable technology and App market. Medibio is listed on the Australian
Securities Exchange. and also trades on the OTCQB Venture Market for early stage
and developing U.S. and international companies. Investors can find Real-Time
quotes and market information for the company
on www.otcmarkets.com and www.asx.com.au.
To learn more about Medibio visit www.Medibio.com.au
(1) http://www.nimh.nih.gov/health/statistics/prevalence/post-traumatic-stress-
disorder-among-adults.shtml
(2) http://www.ptsd.va.gov/public/PTSD-overview/basics/how-common-is-ptsd.asp
+------------------------------------------------------------------------------------+
|Further Information: Website: www.medibio.com.au |
+-------------------------------+---------------------+------------------------------+
|Medibio Shareholder |U.S. Media | |
|Enquiries: |Enquiries: | |
|Jack Cosentino |Nancy Thompson |Australian Media Enquiries: |
|CEO and Managing Director |Vorticom Inc. |Peter Taylor |
|Medibio Limited |nancyt(at)vorticom.com |NWR Communications |
|jack.cosentino(at)medibio.com.au |T: +1 (212) |peter(at)nwrcommunications.com.au|
|T: +1 (952) 465 4787 |532 2208 |T: +61 (0) 412 036 231 |
+-------------------------------+---------------------+------------------------------+
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medibio Limited via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 26.06.2017 - 16:51 Uhr
Sprache: Deutsch
News-ID 549813
Anzahl Zeichen: 10446
contact information:
Town:
Savage
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 227 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Scientific breakthrough on objective diagnosis of PTSD"
steht unter der journalistisch-redaktionellen Verantwortung von
Medibio Limited (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
